- Home
- CRSR vs RGNX Comparison
CRSR vs RGNX Comparison
Compare CRSR & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRSR | RGNX |
|---|---|---|
| Founded | 1994 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 723.6M | 761.9M |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CRSR | RGNX |
|---|---|---|
| Price | $5.46 | $9.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $8.50 | ★ $29.13 |
| AVG Volume (30 Days) | ★ 3.5M | 816.8K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.37 | 23.75 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,472,480,000.00 | $10,393,000.00 |
| Revenue This Year | $0.51 | $127.88 |
| Revenue Next Year | $5.61 | $42.53 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 11.86 | ★ 126.48 |
| 52 Week Low | $4.48 | $5.04 |
| 52 Week High | $12.00 | $16.19 |
Technical Indicators
Market Signals| Indicator | CRSR | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 49.17 | 40.54 |
| Support Level | $5.44 | $7.67 |
| Resistance Level | $6.08 | $9.28 |
| Average True Range (ATR) | 0.47 | 0.60 |
| MACD | 0.05 | 0.16 |
| Stochastic Oscillator | 30.78 | 45.85 |
Price Performance
Historical ComparisonAbout CRSR Corsair Gaming Inc.
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue-generating segment; and Gaming Components and Systems. Geographically, the group derives revenue from the Americas, Europe and the Middle East, and the Asia Pacific.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.